Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Garcia DA, et al. Among authors: alexander jh. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25. Am Heart J. 2013. PMID: 24016506 Clinical Trial.
Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
Serebruany VL, Malinin AI, Callahan KP, Binbrek A, Van De Werf F, Alexander JH, Granger CB, Gurbel PA; Assessment of the Safety and Efficacy of a New Thrombolytic Agent platelet substudy. Serebruany VL, et al. Among authors: alexander jh. Am Heart J. 2003 Apr;145(4):636-42. doi: 10.1067/mhj.2003.210. Am Heart J. 2003. PMID: 12679759 Clinical Trial.
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Among authors: alexander jh. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB; ASSENT-2 and ASSENT-3 Investigators. Curtis JP, et al. Among authors: alexander jh. Am J Cardiol. 2004 Aug 1;94(3):279-83. doi: 10.1016/j.amjcard.2004.04.019. Am J Cardiol. 2004. PMID: 15276088
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Galla JM, et al. Among authors: alexander jh. Am Heart J. 2006 Jan;151(1):16-24. doi: 10.1016/j.ahj.2005.01.045. Am Heart J. 2006. PMID: 16368286
465 results